Results 61 to 70 of about 9,531 (127)
Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development
Cancer Science, Volume 117, Issue 9, Page 2335-2344, September 2026.Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura +3 more
wiley +1 more source
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Journal of Hematology & Oncology, 2020 The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has recently gained interest, and different DDR inhibitors have been developed. Among them, the most promising ones target the WEE1 kinase family, which has a crucial role
Andrea Ghelli Luserna di Rorà +3 more
doaj +1 more source
Early‐Phase Research in Pediatric Neuro‐Oncology
Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley +1 more source
Advanced Science, Volume 13, Issue 44, 7 August 2026.Molecular, genetic, virological, and biochemical analysis in combination with global proteome and phosphoproteome profiling and functional assays were applied to study the role of PR130 in the context of HSV‐1 replication. The observations reveal that host‐intrinsic mechanisms regulate HSV‐1 replication and highlight PR130 as a susceptibility factor of
Johannes Jungwirth +10 more
wiley +1 more source
An Ancestral Mechanism of Calmodulin Binding to Cds1 Kinase Inhibits Catalytic Activity
IUBMB Life, Volume 78, Issue 8, August 2026.ABSTRACT Calmodulin is a highly conserved, calcium (Ca2+) sensor protein that is ubiquitous among eukaryotes. Ca2+ binding to Calmodulin induces a conformational change that facilitates interaction with, and activation of, serine/threonine protein kinases, including members of the CaMK family.
Stephanie A. Manovella +12 more
wiley +1 more source
Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.ABSTRACT We investigated the potential of miR‐640 to downregulate CDK4/6 inhibitor resistance‐associated genes and evaluated its apoptotic, anti‐metastatic and anti‐proliferative effects, both alone and in combination with abemaciclib in breast cancer cells. miR‐640 was identified via GSE126125 dataset analysis.
Ismail Mert Alkac, Cigir Biray Avci
wiley +1 more source
Cell ReportsSummary: DNA damage profoundly affects cancer progression and immune cell function. While research primarily focuses on tumor cells, the effects of DNA damage on immune cells remain understudied.
Ian-Ian Ng +8 more
doaj +1 more source
Discover OncologyBackground Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of white blood cells. Tyrosine kinase inhibitors (TKIs) are the standard treatment; however, resistance to BCR::ABL1 mutations ...
Seiichi Okabe +3 more
doaj +1 more source
Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders. [PDF]
ACS Omega, 2023 Alli VJ, Yadav P, Suresh V, Jadav SS.
europepmc +1 more source